Publications

LES PUBLICATIONS :
(2013 Sep 26. Blood-2013-07-512442. doi: 10.1182/blood-2013-07-512442). Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Voir le détails
(2013 Sep 12; Oncogene 32(37):4331-42. doi: 10.1038/onc.2012.469. Epub 2012 Oct 22). Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Voir le détails
(2013 Sep 10.Ann Hematol). Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Voir le détails
(2013 Oct; Bone Marrow Transplant 48(10):1296-301. doi: 10.1038/bmt.2013.50. Epub 2013 Apr 15). Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.
Voir le détails
(2013 Oct 24; Blood 122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Voir le détails
(2013 May.Ann Hematol.92(5):621-31). High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Voir le détails
(2013 May. Blood. 23;121(21):4280-6. doi: 10.1182/blood-2013-02-453068. Epub 2013 Apr 10). How we treat lower-risk myelodysplastic syndromes.
Voir le détails
(2013 Mar; Rev Med Interne 34(3):159-67. doi: 10.1016/j.revmed.2012.06.009. Epub 2012 Jul 4). [New tools and treatments in myelodysplastic syndromes].
Voir le détails
(2013 Mar. Leukemia Research 37(3):312-9 doi: 10.1016/j.leukres.2012.10.018. Epub 2012 Nov 12). Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
Voir le détails
(2013 Jun. Leukemia. 27(6):1283-90. doi: 10.1038/leu.2013.16. Epub 2013 Jan 16). Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.
Voir le détails
(2013 Jun. Leukemia Research 37(6):637-40). Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Voir le détails
(2013 Jul.Haematologica 98(7):1067-72). A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001.
Voir le détails
(2013 Jul. Leukemia 27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26). A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
Voir le détails
(2013 Jul. J Clin Oncol 20;31(21):2662-70). Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Voir le détails
(2013 Feb. Eur J Haematol 90(2):151-6. doi: 10.1111/ejh.12048. Epub 2013 Jan 9). Disclosure of myelodysplastic syndrome diagnosis: improving patients understanding and experience.
Voir le détails
(2013 Aug.Br J Haematol 162(3):413-415. doi: 10.1111/bjh.12368. Epub 2013 May 9). Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.
Voir le détails
(2013 Aug 13.Leuk Res.2013.07.023. pii: S0145-2126(13)00265-8. doi: 10.1016/j.leukres.2013.07.023). Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Voir le détails
(2013 Apr. Leukemia 27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21). Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Voir le détails
(2013 Mar.Leuk Res 37(3):259-65). Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion:results from a randomized clinical trial.
Voir le détails